MYCN and neuroblastoma: In addition to MYCN amplification, high-risk NB may be categorised into two other distinct molecular subgroups that display either an alternating length of telomeres (ALT) phenotype (circa 24% of high-risk cases) or upstream rearrangements with respect to the telomere reverse transcriptase (TERT) gene (circa 23–31% of high-risk cases) [7,8,9].